



Company Description

GlycoNex specializes in the discovery and the development of antibody-based therapeutics. With a specific focus on glycan-directed cancer therapies, GlycoNex has established an anti-glycan antibody bank, which includes 50+ antibodies.

GlycoNex has developed a comprehensive platform for antibody development, which covers plasmid constructions, stable cell line development, analytical development and all the way to the 50L-production. Based on this platform, GlycoNex has created different types of products including innovative antibodies, biosimilars (ex. Denosumab), and Fc-fusion protein. GlycoNex is looking for opportunities to license products out or co-develop with partners.

Contact Information

Name	Chun-Fu Lin	Position	Director, Manufacture
Tel	+886-2-2697 4168 #133		
E-mail	jflin@glyconex.com.tw		
Address	8 F, No. 97, Sec. 1, Xintai 5 th Rd., Xizhi Dist., New Taipei City 22175, Taiwan (R.O.C.)		
Sectors	Antibody Drug Development, Biosimilar, CDMO Service, Monosaccharide Analysis, Antibody Characterization		